Since inhibition of the COX-2/PGE2 pathway can efficiently enhance responses to ICB in multiple pre-clinical tumour models, it may be that additional stimulation of the immune system is required to observe a therapeutic benefit from chemotherapy and COX-2 inhibitor combinations in certain contexts. The gene discussed is PTGS2; the disease is neoplasm.